There are several recombinant viral vectors available for the delivery of therapeutic genetic cargo to the body’s cells. Recombinant adeno-associated virus vectors (AAV) have become the dominant gene-delivery vector of choice, aimed at curing or treating disease by delivering new or replacement genes to code for therapeutic proteins in humans. AAV offers the advantages of no pathogenicity, efficient long-term gene expression, ease of genetic manipulation, and the property of low, or in many cases, absent immune response. AskBio’s founding team were pioneers in the development of AAV vectors. Our proprietary AAV vectors are a key differentiator for the company.